Patient safety and the value of pharmaceutical intervention in a cancer hospital

Detalhes bibliográficos
Autor(a) principal: Aguiar,Karina da Silva
Data de Publicação: 2018
Outros Autores: Santos,Jamile Machado dos, Cambrussi,Mônica Cristina, Picolotto,Solane, Carneiro,Marcela Bechara
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Einstein (São Paulo)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082018000100210
Resumo: ABSTRACT Objective To demonstrate economic impact of pharmaceutical evaluation in detection and prevention of errors in antineoplastic prescriptions. Methods This was an observational and retrospective study performed in a cancer hospital. From July to August 2016 pharmacists checked prescriptions of antineoplastic and adjuvant drugs. Drug-related problems observed were classified and analyzed concerning drug, pharmaceutical intervention, acceptability and characteristic of the error. In case of problem related to dose, we calculated a deviation percentage related with correct dose and value spent or saved. Data were analyzed using descriptive statistics with frequency and percentage. Results A total of 6,104 prescriptions and 12,128 medications were evaluated. Drug-related problems were identified in 274 (4.5%) prescriptions. Most of them was due to lack of information (n=117; 36.1%). Problems associated with dose accounted for 32.1% (n=98) of the total. In 13 cases (13.3%) ranging of prescribed dose was 50% greater than the correct dose. Intercepted drug-related problems provided savings of R$54.081,01 and expenses of R$20.863,36, therefore resulting in a positive balance of R$33.217,65. Each intervention promoted saving of R$126,78 with an acceptance rate of 98%. Main pharmaceutical interventions were information inclusion (n=117; 36.1%) and dose change (n=97; 29.9%). All errors were classified as error with no harm. Conclusion Simple actions such as prescription checking are able to identify and prevent drug-related problems, avoid financial losses and add immeasurable value to patient safety.
id IIEPAE-1_71921e674f5195d11c29edf14c621bab
oai_identifier_str oai:scielo:S1679-45082018000100210
network_acronym_str IIEPAE-1
network_name_str Einstein (São Paulo)
repository_id_str
spelling Patient safety and the value of pharmaceutical intervention in a cancer hospitalEconomics, pharmaceuticalPharmaceutical servicesMedication errorsDrug prescriptionsAntineoplastic agentsOncology service, hospitalABSTRACT Objective To demonstrate economic impact of pharmaceutical evaluation in detection and prevention of errors in antineoplastic prescriptions. Methods This was an observational and retrospective study performed in a cancer hospital. From July to August 2016 pharmacists checked prescriptions of antineoplastic and adjuvant drugs. Drug-related problems observed were classified and analyzed concerning drug, pharmaceutical intervention, acceptability and characteristic of the error. In case of problem related to dose, we calculated a deviation percentage related with correct dose and value spent or saved. Data were analyzed using descriptive statistics with frequency and percentage. Results A total of 6,104 prescriptions and 12,128 medications were evaluated. Drug-related problems were identified in 274 (4.5%) prescriptions. Most of them was due to lack of information (n=117; 36.1%). Problems associated with dose accounted for 32.1% (n=98) of the total. In 13 cases (13.3%) ranging of prescribed dose was 50% greater than the correct dose. Intercepted drug-related problems provided savings of R$54.081,01 and expenses of R$20.863,36, therefore resulting in a positive balance of R$33.217,65. Each intervention promoted saving of R$126,78 with an acceptance rate of 98%. Main pharmaceutical interventions were information inclusion (n=117; 36.1%) and dose change (n=97; 29.9%). All errors were classified as error with no harm. Conclusion Simple actions such as prescription checking are able to identify and prevent drug-related problems, avoid financial losses and add immeasurable value to patient safety.Instituto Israelita de Ensino e Pesquisa Albert Einstein2018-01-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082018000100210einstein (São Paulo) v.16 n.1 2018reponame:Einstein (São Paulo)instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)instacron:IIEPAE10.1590/s1679-45082018ao4122info:eu-repo/semantics/openAccessAguiar,Karina da SilvaSantos,Jamile Machado dosCambrussi,Mônica CristinaPicolotto,SolaneCarneiro,Marcela Becharaeng2018-05-02T00:00:00Zoai:scielo:S1679-45082018000100210Revistahttps://journal.einstein.br/pt-br/ONGhttps://old.scielo.br/oai/scielo-oai.php||revista@einstein.br2317-63851679-4508opendoar:2018-05-02T00:00Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)false
dc.title.none.fl_str_mv Patient safety and the value of pharmaceutical intervention in a cancer hospital
title Patient safety and the value of pharmaceutical intervention in a cancer hospital
spellingShingle Patient safety and the value of pharmaceutical intervention in a cancer hospital
Aguiar,Karina da Silva
Economics, pharmaceutical
Pharmaceutical services
Medication errors
Drug prescriptions
Antineoplastic agents
Oncology service, hospital
title_short Patient safety and the value of pharmaceutical intervention in a cancer hospital
title_full Patient safety and the value of pharmaceutical intervention in a cancer hospital
title_fullStr Patient safety and the value of pharmaceutical intervention in a cancer hospital
title_full_unstemmed Patient safety and the value of pharmaceutical intervention in a cancer hospital
title_sort Patient safety and the value of pharmaceutical intervention in a cancer hospital
author Aguiar,Karina da Silva
author_facet Aguiar,Karina da Silva
Santos,Jamile Machado dos
Cambrussi,Mônica Cristina
Picolotto,Solane
Carneiro,Marcela Bechara
author_role author
author2 Santos,Jamile Machado dos
Cambrussi,Mônica Cristina
Picolotto,Solane
Carneiro,Marcela Bechara
author2_role author
author
author
author
dc.contributor.author.fl_str_mv Aguiar,Karina da Silva
Santos,Jamile Machado dos
Cambrussi,Mônica Cristina
Picolotto,Solane
Carneiro,Marcela Bechara
dc.subject.por.fl_str_mv Economics, pharmaceutical
Pharmaceutical services
Medication errors
Drug prescriptions
Antineoplastic agents
Oncology service, hospital
topic Economics, pharmaceutical
Pharmaceutical services
Medication errors
Drug prescriptions
Antineoplastic agents
Oncology service, hospital
description ABSTRACT Objective To demonstrate economic impact of pharmaceutical evaluation in detection and prevention of errors in antineoplastic prescriptions. Methods This was an observational and retrospective study performed in a cancer hospital. From July to August 2016 pharmacists checked prescriptions of antineoplastic and adjuvant drugs. Drug-related problems observed were classified and analyzed concerning drug, pharmaceutical intervention, acceptability and characteristic of the error. In case of problem related to dose, we calculated a deviation percentage related with correct dose and value spent or saved. Data were analyzed using descriptive statistics with frequency and percentage. Results A total of 6,104 prescriptions and 12,128 medications were evaluated. Drug-related problems were identified in 274 (4.5%) prescriptions. Most of them was due to lack of information (n=117; 36.1%). Problems associated with dose accounted for 32.1% (n=98) of the total. In 13 cases (13.3%) ranging of prescribed dose was 50% greater than the correct dose. Intercepted drug-related problems provided savings of R$54.081,01 and expenses of R$20.863,36, therefore resulting in a positive balance of R$33.217,65. Each intervention promoted saving of R$126,78 with an acceptance rate of 98%. Main pharmaceutical interventions were information inclusion (n=117; 36.1%) and dose change (n=97; 29.9%). All errors were classified as error with no harm. Conclusion Simple actions such as prescription checking are able to identify and prevent drug-related problems, avoid financial losses and add immeasurable value to patient safety.
publishDate 2018
dc.date.none.fl_str_mv 2018-01-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082018000100210
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S1679-45082018000100210
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.1590/s1679-45082018ao4122
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
publisher.none.fl_str_mv Instituto Israelita de Ensino e Pesquisa Albert Einstein
dc.source.none.fl_str_mv einstein (São Paulo) v.16 n.1 2018
reponame:Einstein (São Paulo)
instname:Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron:IIEPAE
instname_str Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
instacron_str IIEPAE
institution IIEPAE
reponame_str Einstein (São Paulo)
collection Einstein (São Paulo)
repository.name.fl_str_mv Einstein (São Paulo) - Instituto Israelita de Ensino e Pesquisa Albert Einstein (IIEPAE)
repository.mail.fl_str_mv ||revista@einstein.br
_version_ 1752129909188198400